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ABSTRACT 
Mucoadhesive polymers that bind to the gastric mucin or epithelial cell surface are useful in drug delivery for the purpose of increasing 
the intimacy and duration of contact of drug with the absorbing membrane. Mainly synthetic polymers are in use for this purpose. 
Probably the biodegradability of the synthetic polymers are questionable, In the present work mucoadhesive buccal tablets of Tizanidine 
hydrochloride (TZD HCl) were prepared by using locust bean gum that have better mucoadhesive property than synthetic polymer. The 
in-vitro adhesive and mucoadhesive strength and swelling property of mucoadhesive material locust bean gum were evaluated by Share 
Stress and Park and Robinson methods. Buccal formulations of tizanidine HCL tablets were prepared using locust bean gum and 
thickness, hardness, friability, weight variation and assay of tablets were tested. The in-vitro drug release study of tizanidine HCL 
exhibited extended drug release profile for tablets prepared. Higuchi and Peppas data reveals that the drug released by non-Fickian 
diffusion mechanism. The present study shows that formulation containing 50% locust bean gum have greater mucoadhesive property 
than all other formulation.  
Keywords: Mucoadhesive, Tizanidine HCL, and tablets. bioadhesive 
 
INTRODUCTION
Tizanidine HCL is an agonist Fat α2-adrenergic receptor sites and 
presumably reduces spasticity by increasing presynaptic 
inhibition of motor neurons. In animal models, tizanidine has no 
direct effect on skeletal muscle fibers or the neuromuscular 
junction, and no major effect on monosynaptic spinal reflexes. 
The effects of tizanidine are greatest on polysynaptic pathways. 
The overall effect of these actions is thought to reduce facilitation 
of spinal motor neurons. Absolute oral bioavailability of 
tizanidine is approximately 40% (CV = 24%), due to extensive 
first-pass hepatic metabolism. Tizanidine is extensively 
distributed throughout the body with a mean steady state volume 
of distribution of 2.4 L/kg (CV = 21%) following intravenous 
administration in healthy adult volunteers. Tizanidine  is 
approximately 30% bound to plasma proteins. Tizanidine has 
linear pharmacokinetics over a dose of 1 to 20 mg. Tizanidine has 
a half-life of approximately 2.5 hours (CV=33%).1,2,3 
 Buccal drug delivery has been considered as an alternative 
to oral dosing for subjected to degradation in the G I tract or to 
hepatic first pass metabolism. Buccal drug delivery offers a safer 
mode of drug utilization in case of toxicity. Since natural 
polymers are found in abundance, safe, nontoxic, the present study 
was undertaken by using such natural polymers5,6 
 The aim of the present study was to design buccoadhesive 
tablets to release the drug unidirectionally in buccal cavity for 
extended period of time in order to avoid first-pass metabolism for 
improvement in bioavailability, to reduce the dosing frequency 
and to improve patient compliance.Evaluate natural polymer 
Locust been gum in the concentration 20, 30, 40 and 50 mg as a 
mucoadhesive component in buccal tablets, following their 
application to the buccal mucosa. The release characteristics of 
Tizanidine HCL were compared with oral formulation 
 
MATERIALS AND METHOD 
Tizanidine HCL purchased from balaji drugs gujrath, Locust been 
gum Fluka, Japan. Microcrystalline sulphate, magnesium street, 
lactose, Aspartame and ethyl cellulose were purchaised from loba 
chemie Mumbai. India 
Evaluation of Gum 
Organoleptic evaluation, physical evaluation, determination of 
ash value and microbial count of tamarind seed gum were 
performed according to Indian pharmacopeia. 
 
PREPARATION OF BILAYERED BUCCAL TABLET 
Preparation of mucoadhesive layer
4,5,8,9
 
The mucoadhesive layer containing tizanidine HCL (7.5mg) was 
prepared by using 20, 30,40 and 50 mg of badam gum.Various 
components of each formulation were weighed, mixed and passed 
through the mesh (250 micron) to ensure complete mixing. The 
average weight of about 150mg were separately weighed and 
compressed using a 13 mm diameter of a die on an infrared 
hydraulic pellet press using a force of 8 tons for 60 seconds. The 
placebo tablets were also prepared in the same manner. The 
prepared mucoadhesive layers were 13.32 mm in diameter and 
1.10 mm in thickness. 
Formulation of backing layer to the mucoadhesive layer 
 The backing layer was made up of ethyl cellulose. The solution 
was prepared by dissolving 5% ethyl cellulose in chloroform. The 
prepared solution was sprayed onto one surface of the 
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mucoadhesive layer leaving the other side free. Then it was air 
dried at room temperature. 
           The double layered structure design was expected to 
provide drug delivery in a unidirectional fashion to the mucosa, 
avoids loss of drug due to washout of saliva and swelling profile 
of buccal disc can be changed dramatically by the amount of 
backing material and those changes could alter the drug release 
profile 
 
Table. 1.1: Composition of mucoadhesive layer of buccal tablets of Tizanidine HCL with Locust bean gum 
Formulation 
Tizanidine HCL 
(mg) 
Locust bean 
gum (mg) 
Microcrystalline 
cellulose 
(mg) 
Lactos
e 
Aspartame Magnesium 
sterate 
(mg) 
F 1 2 0 141 6 1 1 
F 6 2 20 121 6 1 1 
F 7 2 30 111 6 1 1 
F8 2 40 101 6 1 1 
F9 2 50 91 6 1 1 
 
EVALUATION OF BUCCAL TABLETS 
 All the formulated dosage forms of Tizanidine HCL buccal 
tablets have been subjected to the following quality control test. 
Uniformity of weight and medicament content
11,12
 
 Test for uniformity of weight of tablets was done according 
to I.P. ten tablets from each batch were evaluated for uniformity in 
tablet weight. Ten tablet from each batch were powdered 
individually and a quality equivalent to 7.5 mg of Tizanidine HCL 
was accurately weighed and transfer to a volumetric flask 
containing 50 ml of phosphate buffer (pH 6.8), sonicated for 30 
minutes, and stirred continuously for 8 hours on a magnetic stirrer 
the volume was made unto 100ml with phosphate buffer pH6.8 
and the absorbance were measured in a UV spectrophotometer at 
276 nm. 
Hardness and friability testing
11,12
 
 Hardness and friability of each ten randomly ,selected 
tablets of each formulation using Erweka hardness tester (TBH30) 
and the Erweka friabilitor (GmbH,Germany) respectively. 
Infrared (IR) absorption spectroscopy 
To investigate any possible interactions between the drug and the 
polymers, the IR spectra of pure drug Tizanidine HCL and its 
physical mixtures (1:1) with badam gum were carried out using 
FT R--8400S(CE),SHIMADZU spectrophotometer. The samples 
were prepared as KBr disks compressed under a pressure of 6 
ton/nm2. The wavelength selected ranged between 400 and 
4000cm-1. The data are shown in fig.1.1-1.3 
 
 
 
 
Fig: 1.1: IR spectrum of Tizanidine HCL 
 
Fig: 1.1: IR spectrum of Locust bean gum 
 
Fig: 1.1: IR spectrum of Tizanidine HCL+ Locust bean gum 
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Bioadhesion study
11,12
 
In vitro bioadhesion study  
 Satisfactory bio adhesion is essential for successful 
application of a buccal bioadhesive drug delivery system. It 
implied the strength of attachment of the dosage form to biological 
tissue. Several techniques for in vitro determination of 
bioadhesion have been reported, which include tensile testing 
shear stress testing, adhesion weight method,fluresent prob 
method , flow channel techniques and colloidal gold staining 
method.In our study the polymers evaluated using TA.XT2 
texture analyzer equipment rabbit buccal mucosa as a model tissue 
under simulates buccal condition 
Bioadhesion measurement 
 A TA.XT2 texture (stable Mirosystem,haslemere,surrey, 
U.K)equipped with a 5g load cell was employed to determine the 
bioadhesion using pig buccal mucosa as the model tissue. The 
buccal mucosa was stored frozen in a simulated saliva solution 
and thawed to room temperature before used. The pig buccal 
mucosa was mounted on to a cylindrical Perspex support of 2cm 
diameter and 2cm length and secured with a string. A foam type 
was placed underneath the porcine buccal mucosa on the Perspex 
support at the cross sectional end to provide cushioning effect. 
The pig buccal mucosa was further secured by placing an 
aluminium cap over the Perspex support. A circular hole of 17mm 
diameter was made on the top of the cap to expose the buccal 
membrane for contact with the tablet during measurements. The 
whole Perspex support was the positioned at the bottom of the 
measuring system and held in place by a clamp. The tablet was 
fixed to another Perspex support of similar dimension using a 
double sided tape and the support was then screwed on to the 
upper probe of instrument. These two Perspex support were 
aligned to ensure that the tablet would coming to direct contact 
with the exposed surface of buccal mucosa when the upper tablet 
support was lowered on measurements were conducted at a room 
temperature of 250c and a relative humidity of 52-60% 
 During measurements, 200µlof stimulated saliva solution 
was evenly spread on the surface of tissues. The upper Perspex 
support was lowered at sapped of 1mm/sec until contact was made 
with the tissue and the contact force of .5N was applied. At 
various contact times 5, 10,15,20,25 and 30 min. The detachment 
force in ‘N’ was measured. 
SWELLING STUDY
14,15,17 
 The swelling index of the tablet was evaluated for six 
tablets of each formulation. These were weighed and placed 
separately in pre-weighed basket made of stainless steel mesh. 
The total weight was recorded (W2). This basket was placed in 
plastic vessel containing 4 ml of isotonic buffer (pH6.8) in an 
incubator at 370C. At time intervals 0.5,1,2,3 and 4 hrs excess 
water was carefully removed and the swollen tablets were 
weighed (W2). The swelling index was determined from formula  
     Swelling index =   )(W weight Initial
)W W(index  Swelling
1
12 
          
 
SURFACE pH OF THE TABLET
19,20
 
 The surface pH of the tablet was determined to investigate 
the effect of pH on the bioadhesion and possible side effects of the 
tablets in vivo. This was determined by allowing the tablet to 
swell in 1.0 ml of demineralised water (pH 6.8) for 2 hrs. A 
combined glass pH electrode was brought in contact of the 
swollen tablet and the pH measured after 1 min equilibrium. 
 
INVITRO DRUG RELEASE STUDIES 
Dissolution studies
12,14,19,21
 
 It has been reported that the normal pH of human saliva 
varies from 5.8 to 7.8 with an average of 6.8. So the release studies 
were conducted in the pH 6.8 to find out the amount of drug 
release into the solution from the buccal tablet before diffusion 
through the membrane. For the dissolution study of the buccal 
tablets a specially designed glass cylinder closed at one end and 
opened at the other end was employed. This glass cylinder allows 
the tablets to dissolve from the fixed place without any movement 
(since the tablet should release the drug from a fixed area in the 
buccal region). 
Tizanidine HCL buccal tablet 
 Release of Tizanidine HCL from buccal tablets was studied 
in phosphate buffer of 6.8 pH (900ml) using a USP XXI/XXII 
dissolution rate apparatus, with a paddle rotating at a rate of 75 
rpm and at 370c  
 
RESULTS AND DISCUSSION 
Evaluation of tablet 
Table 1.1 shows the composition of buccal tablets. The 
microcrystalline cellulose added in the formulation as direct 
compression adjuvant. 
  Tablet hardness varied between 4.7and 5.0kg/cm2 and 
friability ranged between 0.5 and 0.7%. Tablet weight varied 
between 147.2 and 150.6 mg and the assay content of Tizanidine 
HCL varied between 98.8 and 99.7% 
Thus all the parameters of the compressed tablets were practically 
with in control. 
Bioadhesion study 
 The profile showing the mean value of locust bean Gum, 
following their application to excised rabbits intestinal mucosa is 
shown in Fig.1.4 , . It can be noted that the mean values of force of 
detachment increased with time and reached a plateau at later time 
points. The mean values of force of detachment were grater for 
formulation containing 50 mg of locust bean Gum and the 
bioadhesive strength increased with increase in concentration of 
locust bean Gum 
 
Fig. 1.4 : The force of detachment from rabbit intestine for directly 
compressed Tizanidine HCL buccal tablets containing 20, 30,40 
and 50 mg of locust been gum. All data points represent the mean 
value ± standard deviation of three experiments 
Swelling index  
The swelling index for the various formulations is shown in 
Fig1.5. These profiles indicate the uptake of water into the tablet 
matrix producing an increase in weight. 
Formulations F6, F7, F8 and F9 containing Locust Bean Gum 
showed faster water uptake increased with increase in time to 
become fully hydrated. Higher concentration of locust bean gum 
displays a greater hydration capacity. The capacity of the 
formulation to take up water is an important intrinsic parameter of 
polymeric system in consideration of release of drug on mucosal 
surface. 
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Fig. 1.5: Swelling index of Tizanidine HCL buccal tablets using 
Locust bean gum 
Surface pH 
An acidic or alkaline pH may cause irritation to buccal mucosa. 
The surface pH of tablet was determined in order to investigate the 
possibility of any side effects in vivo. The surface pH of the tablet 
has been given in Table 1.2. The surface pH of all the formulation 
was found to be within the pH range of 5-7 (salivary pH) and 
hence these formulations do not produce any irritation in the 
buccal cavity. 
Table .1.2 :Surface pH of Tizanidine HCL buccal tablets 
containing Locust Bean Gum 
Drug + Polymer Formulation Surface pH 
Tizanidine HCL 
+ 
Locust bean gum 
F 1 7.1 
F 6 6.4 
F 7 6.2 
F8 6.5 
F9 6.6 
Drug release characteristics 
The drug release profiles from the prepared Tizanidine HCL 
buccal tablets containing various concentration of locust bean 
gum are shown in Fig. 1.6 
Sustained release of Tizanidine HCL was obtained from F6, F7, 
F8 and F9 and with almost 102.88, 95.87, 96.09 and 90.64 in 13th 
hour respectively. 
Increase in concentration of locust bean gum decreased the release 
of Tizanidine HCL. 
 
Fig. 1.6 Cumulative percentage release of Tizanidine HCL buccal 
tablets containing 20, 30, 40 and 50 mg of Locust bean Gum in 
phosphate buffer pH 6.8 
Drug release kinetics  
To examine the release mechanism of Tizanidine HCL from the 
prepared bioadhesive tablets, the results were analysed according 
to the following equation 
Ktn
M
Mt

  
Where Mt/M is fractional drug released at time t, k is the kinetic 
constant incorporating structural and geometric characteristic of 
drug/polymer system (device) and n is diffusional expectorant that 
characterizes the mechanisms of drug release. For non – Fickian 
release, the n value falls between 0.5 and 1(0.5<n<1.0), whereas in 
the case of Fickian diffusion, n=0.5, for zero order release (case II 
transport) n=1 and for super case II transport, n>1. The values of n 
as estimated bilinear regression of log Mt/M   vs log (t) of different 
formulations are shown in Table 1.3 
 
 
Table . 1.3: Kinetic release constants (K) and diffusion exponents 
(n) after fitting the release  data to simple power law (logMt/mα Vs 
Log t) 
Drug+polymer 
Formulation 
code 
n 
value 
K 
value 
Release 
characteristics 
Tizanidine 
HCL + Locust 
bean gum 
F6 0.50 3.72 fickain 
F7 0.50 7.98 fickain 
F8 0.50 3.72 fickain 
F9 0.51 3.95 non-fickain 
F1 0.34 9.33  
n2 = the diffusion exponent of the release mechanism; n= 0.5 for 
Fickian diffusion mechanism;  
n= 1 for zero order release (case II transport); n lies between 0.5 
and 1.0(0.5<n<1)  
for non- fickain (anomalous) release and n> 1 for super case II 
transport 
Data analysis   
        The data obtained from dissolution kinetic studies were 
analyzed using PCP Disso V2.08 software. 
        Dissolution profile for Locust bean gum in Fig 1.3 
demonstrates a diffusion release of Tizanidine HCL from 
formulation containing 20, 30 and 40  mg of locust bean and 
swelling and erosion mechanism for formulation contains 50 mg 
of locust bean gum  
T50% release 
 The time for 50% (T50%) release of Tizanidine HCL from 
the prepared buccal tablets were estimated by linear regression of 
log MT/Mα vs log (t) of different formulations are shown in 
table1.4. The results were clearly indicated increasing the half life 
(T50%) of Tizanidine HCL release from the prepared tablets by 
increasing the concentration of locust bean gum. 
Table .1.4  : Time (H) For 50% Tizanidine HCL release from the 
prepared buccal tablet 
Drug + polymer Formulation code T50% 
 
Tizanidine HCL+  
Locust bean gum 
F6 4.45 
F7 4.47 
F8 4. 84 
F9 4.9 
 
CONCLUSION 
Increase in concentration of locust bean gum increases in the 
bioadhesive strength and swelling ratio in the 50 mg of locust bean 
gum. Cumulative percentage release decreases with increase in 
concentration of tamarind seed gum. The formulations F6, F7and 
F8 shows fickain diffusion mechanism. And formulation F9 
shows non fickain mechanism. Fickain release kinetics involving 
diffusion mechanism and non-Fickian release kinetics involving a 
combination of both diffusion and chain relaxation mechanism 
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